Fate Therapeutics (FATE) Interest & Investment Income (2013 - 2026)
Fate Therapeutics (FATE) posted Interest & Investment Income of $1.9 million for Q1 2026, down 15.9% on a QoQ basis from $2.2 million in Q4 2025, and down 44.03% year-over-year from $3.3 million in Q1 2025.
Fate Therapeutics (FATE) Interest & Investment Income (2013 - 2026) Analysis & Trends
Fate Therapeutics' Interest & Investment Income history runs 14 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- Quarterly Interest & Investment Income fell 44.03% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (down 41.83% YoY) and the FY2025 annual result came in at $11.1 million, down 36.07% from the prior year.
- Interest & Investment Income was $1.9 million for Q1 2026 at Fate Therapeutics, down from $2.2 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.8 million in Q2 2024 and bottomed at $418000.0 in Q1 2022.
- A 5-year average of $3.1 million and a median of $3.3 million in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 869.7% — and 2026, when it tumbled 44.03%.
- Fate Therapeutics' Interest & Investment Income stood at $2.9 million in 2022, then jumped by 53.26% to $4.4 million in 2023, then retreated by 12.23% to $3.9 million in 2024, then plunged by 42.69% to $2.2 million in 2025, then slipped by 15.9% to $1.9 million in 2026.
- Business Quant data shows FATE's Interest & Investment Income at $1.9 million in Q1 2026, $2.2 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Fate Therapeutics | 293.47 Mn | 293.47 Mn | - | 1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.87 Mn |
| Dec 31, 2025 | 2.22 Mn |
| Sep 30, 2025 | 2.58 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Mar 31, 2025 | 3.34 Mn |
| Dec 31, 2024 | 3.87 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Jun 30, 2024 | 4.83 Mn |
| Mar 31, 2024 | 4.15 Mn |
| Dec 31, 2023 | 4.41 Mn |
| Sep 30, 2023 | 4.70 Mn |
| Jun 30, 2023 | 4.38 Mn |
| Mar 31, 2023 | 3.69 Mn |
| Dec 31, 2022 | 2.88 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 757,000.00 |
| Mar 31, 2022 | 418,000.00 |
| Dec 31, 2021 | 297,000.00 |
| Sep 30, 2021 | 289,000.00 |
| Jun 30, 2021 | 346,000.00 |